Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/30215
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sudha, Thangirala | - |
dc.contributor.author | Bharali, Dhruba J. | - |
dc.contributor.author | Davis, Paul J. | - |
dc.contributor.author | Mousa, Shaker A. | - |
dc.date.accessioned | 2023-01-02T08:21:36Z | - |
dc.date.available | 2023-01-02T08:21:36Z | - |
dc.date.issued | 2020-01-27 | - |
dc.identifier.citation | Coşkun, M. D. vd. (2020). "Alpha v beta 3 integrin antagonists enhance chemotherapy response in an orthotopic pancreatic cancer model". Frontiers in Pharmacology, 11. | en_US |
dc.identifier.issn | 1663-9812 | - |
dc.identifier.uri | https://doi.org/10.3389/fphar.2020.00095 | - |
dc.identifier.uri | https://www.frontiersin.org/articles/10.3389/fphar.2020.00095/full | - |
dc.identifier.uri | http://hdl.handle.net/11452/30215 | - |
dc.description.abstract | Pancreatic cancer decreases survival time and quality of life because of drug resistance and peripheral neuropathy during conventional treatment. This study was undertaken to investigate whether alpha v beta 3 integrin receptor antagonist compounds NDAT and XT199 can suppress the development of cisplatin resistance and cisplatin-induced peripheral neuropathy in an orthotopic pancreatic SUIT2-luc cancer cell mouse model. Anticancer effects of these compounds and their combination with cisplatin were assessed in this tumor mouse model with bioluminescent signaling and histopathology, and a cytokine assay was used to examine expression of inflammatory cytokines IL-1 beta, IL-6, IL-10, and TNF-alpha from plasma samples. To determine the neuroprotective effects of the compounds on cisplatin-induced peripheral neuropathy, behavioral hind-limb posture of the mice was evaluated. The combination therapy of NDAT or XT199 with cisplatin elicited greater inhibition of tumor growth and increased tumor necrosis compared to cisplatin alone. NDAT and XT199 in combination with cisplatin significantly decreased expression of pro-inflammatory cytokines IL-1 beta, IL-6, and TNF-alpha and significantly increased expression of anti-inflammatory cytokine IL-10 in comparison to cisplatin alone. Cisplatin-treated groups showed stocking-glove hind-limb posture, whereas NDAT and XT199 with cisplatin-treated groups displayed normal hind-limb posture. Results clearly suggest that NDAT and XT199 treatment with cisplatin that inactivates NF-kappa B may contribute to increased antitumor and anti-inflammatory efficacy as well as alleviate cisplatin-mediated loss of motor function in this pancreatic tumor mouse model. | en_US |
dc.description.sponsorship | Pharmaceutical Research Institute at Albany College of Pharmacy Health and Sciences | en_US |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Media | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Pancreatic cancer | en_US |
dc.subject | NF-kappa B | en_US |
dc.subject | Cisplatin | en_US |
dc.subject | Alpha v beta 3 integrin receptor antagonist | en_US |
dc.subject | Peripheral neuropathy | en_US |
dc.subject | Motor dysfunction | en_US |
dc.subject | Induced peripheral neurotoxicity | en_US |
dc.subject | Tetraiodothyroacetic aicd | en_US |
dc.subject | Multidrag-resistance | en_US |
dc.subject | Thyroid-hormone | en_US |
dc.subject | Alpha(v)beta(3) antagonists | en_US |
dc.subject | Inflammatory cytokines | en_US |
dc.subject | Targeted delivery | en_US |
dc.subject | Oxidative stress | en_US |
dc.subject | Drug-resistance | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.title | Alpha v beta 3 integrin antagonists enhance chemotherapy response in an orthotopic pancreatic cancer model | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000525314000001 | tr_TR |
dc.identifier.scopus | 2-s2.0-85082498621 | tr_TR |
dc.relation.tubitak | 2214-A (1059B141401097) | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Bursa Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Biyoloji Bölümü. | tr_TR |
dc.contributor.orcid | 0000-0002-4177-3478 | tr_TR |
dc.identifier.volume | 11 | tr_TR |
dc.relation.journal | Frontiers in Pharmacology | en_US |
dc.contributor.buuauthor | Coşkun, Melis Debreli | - |
dc.contributor.buuauthor | Çelikler, Serap | - |
dc.contributor.researcherid | CML-2517-2022 | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.identifier.pubmed | 32174830 | tr_TR |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q1 | en_US |
dc.contributor.scopusid | 57194630463 | tr_TR |
dc.contributor.scopusid | 8234554800 | tr_TR |
dc.subject.scopus | Integrin; Thyroid Hormones; Nano-Diamino-Tetrac | en_US |
dc.subject.emtree | 3 [3 [3 (4, 5 dihydroimidazol 2 ylamino)propyloxylisoxazol 5 yl]carbonylamino] 2 (phenylsulfonylamino)propionic acid | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Cisplatin | en_US |
dc.subject.emtree | Interleukin 10 | en_US |
dc.subject.emtree | Immunoglobulin enhancer binding protein | en_US |
dc.subject.emtree | Interleukin 1beta | en_US |
dc.subject.emtree | Interleukin 6 | en_US |
dc.subject.emtree | Receptor blocking agent | en_US |
dc.subject.emtree | Tumor necrosis factor | en_US |
dc.subject.emtree | Unclassified drug | en_US |
dc.subject.emtree | Vitronectin receptor | en_US |
dc.subject.emtree | Vitronectin receptor antagonist | en_US |
dc.subject.emtree | Xt 199 | en_US |
dc.subject.emtree | [[4 [4 [3 [3 [poly 2 (2 hydroxyacetotoxy)]propanamido]aminopropoxy] 3,5 diiodophenoxy] 3,5 diiodophenyl] acetic acid] | en_US |
dc.subject.emtree | Animal cell | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Animal tissue | en_US |
dc.subject.emtree | Antineoplastic activity | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Bioluminescence | en_US |
dc.subject.emtree | Body position | en_US |
dc.subject.emtree | Cancer combination chemotherapy | en_US |
dc.subject.emtree | Cancer inhibition | en_US |
dc.subject.emtree | Cancer model | en_US |
dc.subject.emtree | Cancer resistance | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Drug potentiation | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Hindlimb | en_US |
dc.subject.emtree | Histopathology | en_US |
dc.subject.emtree | Interleukin 10 blood level | en_US |
dc.subject.emtree | Interleukin 1beta blood level | en_US |
dc.subject.emtree | Interleukin 6 blood level | en_US |
dc.subject.emtree | Monotherapy | en_US |
dc.subject.emtree | Motor dysfunction | en_US |
dc.subject.emtree | Mouse | en_US |
dc.subject.emtree | Neuroprotection | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Pancreas cancer | en_US |
dc.subject.emtree | Pancreatic cancer cell line | en_US |
dc.subject.emtree | Peripheral neuropathy | en_US |
dc.subject.emtree | Protein blood level | en_US |
dc.subject.emtree | Protein determination | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Signal transduction | en_US |
dc.subject.emtree | SUIT2-luc cancer cell line | en_US |
dc.subject.emtree | Transcription initiation | en_US |
dc.subject.emtree | Treatment response | en_US |
dc.subject.emtree | Tumor necrosis | en_US |
dc.subject.emtree | Tumor necrosis factor blood level | en_US |
Appears in Collections: | PubMed Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Coskun_vd_2020.pdf | 2.61 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.